Harvest One Cannabis Stock (TSXV: HVT) (OTC: HRVOF) - Investor Dashboard


➔ Harvest One Cannabis
TSX Venture Exchange: HVT
OTC Ticker: HRVOF
Sector: Healthcare
Industry: Legal Cannabis
Country: Canada
Employees:  26
Established: 2015
CEO: Andreas Gedeon

Summary

Fiscal Year-End: June
License Renewal Month: June
Licenses: 1
Licensed Capacity:  100KG
Number of Patients: 0
Headquarters: Vancouver, BC

Financials (09/30/17)

Cash on hand: $12.16mm
Fixed Investment: $8.40mm
Shareholders’ Equity: $21.95mm
Revenues – Last Quarter: $175K
Adj. Gross Margin : -17.5%
EPS : -$0.02

Capital Structure (01/31/18)

Last Financing:  22.11mm Units at $1.82
Basic Shares: 111.3mm
Warrants: 50.1mm
Options: 8.1mm
Diluted Shares: 193.3mm

Company Brief

Harvest One is a holding company that owns Canadian ACMPR licensed producer United Greeneries and Swiss medical cannabis brand Satipharm. United Greeneries received its cultivation license in June 2016 and is focused on expanding the capacity at the Chemainus Facility to ~8,500kg annual production in 2018.

Satipharm, which is generating revenue, focuses on oral delivery technologies. It has been producing Gelpell ® Microgel Capsules, a pharmaceutical grade product with GMP production, since May 2015. The company is focusing initially on Germany and Poland and will be entering other EU countries this year. Satipharm plans to export Gelpell ® Microgel products into the Canadian ACMPR market and the Australian market and also plans to license or introduce products into regulated cannabis markets internationally.

Featured Video

The United Greeneries’ flagship facility on Vancouver Island in Canada.


HVST shareholders will have significant exposure to two of the largest commercial opportunities in the global cannabis sector

united-greeneries-satipharm-HVST

United Greeneries is a Canadian ACMPR Licensed Producer and will be HVST’s horticultural arm and recreational brand.

  • ACMPR (MMPR) Licensed Producer Duncan Facility in BC
  • Current capacity of ~1,000 kg/year
  • Fully funded Chemainus Facility in BC targets 8500 kg/year
  • Lucky Lake Facility in SK targets 12,000 kg/year
  • Outdoor grow in BC targets 50,000 kg/year with regulatory changes

Satipharm is specialized in the development and manufacturing of cannabis- based health products and will be the company’s medical and health brand

  • Flagship Gelpell ® Microgel Capsules to lead growth
    • Near-term growth from supplement sales in EU
    • Mid-term growth from entry into regulated markets (Canada, Australia, etc.)
    • Significant growth opportunities globally
  • Global exclusive rights to Gelpell ® on cannabis applications; Gelpell Phase 1
  • Growing portfolio of delivery technology IP

Meet the CEO

A brief Q&A with Harvest One CEO Andreas Gedeon

Focused on recreational and medical markets
HVST will be a well-financed, growth- oriented cannabis company focused on supplying Canadian and international medical and recreational cannabis markets through two distinct operating brands:

United Greeneries
Canadian ACMPR Licensed Producer with focus on large-scale horticultural operations for the upcoming Canadian recreational cannabis market

Satipharm
International medical cannabis brand with focus on oral delivery technologies for strategic entry in emerging medical cannabis markets and the existing medical cannabis market in Canada


Highlights

  • Recreational and medical focus
  • Two Brands
    • United Greeneries focused on large-scale production
    • Satipharm focused on oral delivery technologies
  • Serving Canada and international markets
  • Recent capital raises leave company with $80 million cash position

Growth Strategy

  • Increase Chemainus Facility capacity to 8500 kg
  • Complete Lucky Lake Facility ACMPR application process
  • With regulatory changes, use 398 acres in BC for outdoor grow
  • Expand Satipharm distribution in Europe in near-term and prepare to export to Canada & Australia

Differentiators

  • Three indoor production facilities in two provinces
  • Wholesale rather than investing in competitive medical distribution in Canada
  • In-house QA/QC laboratory
  • Technology-driven portfolio of health products
  • Active in European CBD markets and engaged in clinical trials
  • Site selected for potential outdoor grow

Institutional Analyst Coverage


Curated Stories & News


Visit Harvest One Cannabis, Inc.
at www.harvestone.com.

New Cannabis Ventures in partnership with due diligence platform 420Investor, is the definitive source for fact-based, data-driven, financial information and relevant company news for qualified publicly traded cannabis companies. NCV extracts and parses only the most important content. Information is provided “as is” and solely for informational purposes, not for trading or advice. Harvest One Cannabis, Inc., is a client of NCV Media, LLC. Read our full disclaimer.